Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis Technologies' subsidiary MitoCareX Bio Ltd. announced the appointment of Prof. Dan T. Major to its Scientific Advisory Board to strengthen its computational drug discovery capabilities. Prof. Major, a computational chemistry expert from Bar-Ilan University, will advise on in silico drug-discovery approaches and computational methods to support MitoCareX's expansion of internal scientific capabilities and prioritization of discovery programs.